作者: Jory Baldridge , Kent Myers , David Johnson , David Persing , Christopher Cluff
DOI: 10.1007/978-1-59259-970-7_12
关键词:
摘要: MPL adjuvant, a monophosphoryl lipid A (MLA) derivative of the lipopolysaccharide (LPS) from Salmonella minnesota R595, and RC-529, synthetic mimetic, are promising adjuvant candidates for number human vaccines have been shown to be safe, well-tolerated, effectively enhance immune responses co-administered vaccine antigens. Preliminary evidence suggests that, like LPS, MLA RC-529 activate cells via pattern recognition receptor, Toll-like receptor 4 (TLR4).